University of Leicester-ko ikertzaileekin lankidetzan egindako argitalpenak (2)

2016

  1. Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy

    ESMO Open, Vol. 1, Núm. 6

2013

  1. Strategies for improving outcomes in NSCLC: A look to the future

    Lung Cancer, Vol. 82, Núm. 3, pp. 375-382